Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude sur Selinexor, en association avec le carfilzomib, le daratumumab ou le pomalidomide chez des patients atteints de myélome multiple

18 septembre 2026 mis à jour par: Hackensack Meridian Health

Une étude de phase 2B sur Selinexor (KPT-330), en association avec le carfilzomib, le daratumumab ou le pomalidomide chez des patients atteints de myélome multiple en rechute sous traitement actuel

This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide.

Multiple Myeloma patients with documented disease progression or refractory disease while on current treatment with any carfilzomib-containing regimen (arm 1), any pomalidomide-containing regimen (arm 2) or any daratumumab-containing regimen (exploratory arm) will be included in the study. Patients will be assigned to the respective groups according to their current treatment. If a subject has received more than one of the above therapies, then assignment will be made at their physician's discretion (e.g treatment decision can be made based upon patient and physician preferred tolerance.).

Patients will receive treatment until progressive disease (PD), death, toxicity that cannot be managed by standard of care, or withdrawal, whichever occurs first.

Aperçu de l'étude

Description détaillée

This is a Phase 2b, two-arm, open-label, multicenter study of Sd (selinexor 100, 80 or 60 mg) in combination with carfilzomib, or pomalidomide in patients with MM previously treated with carfilzomib or pomalidomide respectively, and refractory to prior treatment. An additional exploratory arm will focus on patients treated with SD in combination with daratumumab.

This study will enroll approximately 96 patients overall (43 in each of the arms and 10 additional patients in the exploratory arm. Patients will be assigned to the respective arms based on their previous treatment.

Patients who are relapsed or refractory to their current carfilzomib-based regimen will be enrolled on Arm 1 and will receive the following treatment regimen on a 28-day cycle:

Carfilzomib 56 mg/m2 on days 1, 8 and 15. They will also receive dexamethasone 40 mg (or 20 mg if patient is ≥ 75 years old) once weekly and Selinexor 80 mg on days 1, 8 and 15.

Patients who are relapsed or refractory to their current pomalidomide-based regimen will be enrolled on Arm 2 and will receive the following treatment regimen on a 28-day cycle:

Pomalidomide 4 mg po daily for 21 days combined with Dexamethasone 40 mg (or 20 mg if patient is ≥ 75 years old) once weekly and Selinexor 60 mg days 1, 8 and 15.

For arms 1 and 2, 13 patients will be accrued in each arm in the first stage. If there are 3 or fewer responses in these 13 patients, the study will be stopped. Otherwise, 30 additional patients will be accrued for a total of 43 (in each arm).

Finally, in the exploratory arm, we will enroll up to 10 patients who are relapsed or refractory to their current daratumumab-based regimen. Patients enrolled on the exploratory arm will receive the following treatment regimen on a 28-day cycle:

Daratumumab on current schedule (16 mg/kg IV days 1,8,15,22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on) combined with Dexamethasone 40 mg once weekly (or 20 mg if patient is ≥ 75 years old) and Selinexor 100 mg once weekly.

The Investigator may remove a patient from study treatment using criteria described in Section 10.2. Patients may decide to discontinue study treatment for any reason. Patients who elect to discontinue study treatment should be encouraged to continue in the study so that follow-up information on disease progression, other antineoplastic therapy, symptoms and survival status may be obtained. However, patients may elect to withdraw consent and decline further participation in the trial at any time.

The Investigator must determine the primary reason for a patient's discontinuation of study treatment and record this information on the electronic case report form (eCRF). Patients who are prematurely withdrawn from study treatment are not eligible to re-initiate study treatment on this protocol at a later date.

Type d'étude

Interventionnel

Inscription (Estimé)

96

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • District of Columbia
      • Washington D.C., District of Columbia, États-Unis, 20007
        • Recrutement
        • Lombardi Comprehensive Cancer Center
        • Chercheur principal:
          • Kimberly Doucette, MD
        • Contact:
    • New Jersey
      • Hackensack, New Jersey, États-Unis, 07601
        • Recrutement
        • John Theurer Cancer Center
        • Contact:
        • Contact:
        • Chercheur principal:
          • Noa Biran, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age ≥18 years at time of informed consent.

  2. Histologically confirmed MM and evidence of disease progression while on one of the below MM regimens:

    • Arm 1: Refractory to or disease progression while on a carfilzomib-containing regimen
    • Arm 2: Refractory to or disease progression while on a pomalidomide-containing regimen
    • Exploratory Arm: Refractory to or disease progression while on a daratumumab-containing regimen
  3. Measurable disease as defined: Serum M-protein ≥ 0.5 g/dL; urine M-protein excretion at least 200 mg/24h; serum FLC ≥ 100 mg/L, provided that FLC is abnormal; if serum protein electrophoresis is felt to be unreliable for routine M-protein measurement (i.e. IgA MM) then quantitative Ig levels by nephelometry or turbidometry are acceptable; for non-secretory disease, bone marrow plasma cells ≥ 20% or a biopsy-proven target lesion by PET/CT or MRI is acceptable

  4. Documented evidence of disease progression (by IMWG criteria) or refractory disease on the current treatment as defined as:

    • Achieving SD or less for ≥ 1 cycle during treatment with regimens stated in #2 (i.e. relapsed) OR
    • <25% response (i.e. never achieved MR) or PD during or within 60 days from the end-of most recent MM regimen as listed in #2 (i.e. refractory).
  5. Any non-hematological toxicities (except for peripheral neuropathy) that patients experienced from treatments in previous regimens have resolved to Grade 2 or less by Cycle 1 Day 1.

  6. ECOG 2 or less

  7. Adequate hepatic function within 28 days prior to C1D1:

    1. Total bilirubin < 1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 × ULN), and
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to <2 × ULN.
  8. Adequate renal function within 28 days prior to C1D1 as determined by estimated creatinine clearance of ≥ 30 mL/min, calculated using the Cockcroft and Gault formula (140 - Age) • Mass (kg)/ (72 • creatinine mg/dL); multiply by 0.85 if female (Cockcroft 1976).

  9. Adequate hematopoietic function within 7 days prior to C1D1: total white blood cell (WBC) count ≥1500/mm3, absolute neutrophil count ≥1000/mm3, hemoglobin ≥8.5 g/dL and platelet count ≥75,000/mm3 (patients for whom <50% of bone marrow nucleated cells are plasma cells) or ≥50,000/mm3 (patients for whom ≥50% of bone marrow nucleated cells are plasma cells).

    1. Patients receiving hematopoietic growth factor support, including erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (eg, eltrombopag, romiplostim, or interleukin-11) must have a 2-week interval between growth factor support and the Screening assessments, but they may receive growth factor support during the study.

    2. Patients must have:

      • At least a 2-week interval from the last red blood cell (RBC) transfusion prior to the Screening hemoglobin assessment, and
      • At least a 1-week interval from the last platelet transfusion prior to the Screening platelet assessment.

    However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study.

  10. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment.

Exclusion Criteria:

  • Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:

    1. Smoldering MM
    2. Radiation therapy, chemotherapy or immunotherapy other than above stated regimens in #2 ≤2 weeks prior to C1D1. Patients on long-term glucocorticosteroids during screening do not require a washout period. Prior RT is permitted for treatment of fractures or to prevent fractures as well as for pain management.
    3. Active graft versus host disease after allogeneic stem cell transplant.
    4. Life expectancy <3 months.
    5. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.
    6. Has any concurrent medical condition or disease (eg, uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures.
    7. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.
    8. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.
    9. Pregnant or breastfeeding females.
    10. Body surface area (BSA) <1.4 m2 at baseline, calculated by the Dubois (Dubois 1916) or Mosteller (Mosteller 1987) method.
    11. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.
    12. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).
    13. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.
    14. Contraindication to any of the required concomitant drugs or supportive treatments.
    15. Patients unwilling or unable to comply with the protocol

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Carfilzomib-containing Regimen

Carfilzomib 56 mg/m2 on days 1, 8 and 15. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.

Selinexor 80 mg on days 1, 8 and 15.

Selinexor 80 mg PO on days 1, 8 and 15

Autres noms:
  • KPT-330

56 mg/m2 IV on days 1, 8 and 15

Autres noms:
  • Kyprolis

20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22

Autres noms:
  • Dextenza, Ozurdex, Neofordex, autres
Expérimental: Pomalidomide-containing Regimen

Pomalidomide 4 mg po daily for 21 days. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.

Selinexor 60 mg on days 1, 8 and 15.

20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22

Autres noms:
  • Dextenza, Ozurdex, Neofordex, autres

Selinexor 60 mg PO on days 1, 8 and 15

Autres noms:
  • KPT-330

4 mg PO daily for 21 days

Autres noms:
  • Pomalyste
Expérimental: Exploratory/Daratumumab-containing Regimen

Daratumumab on current schedule (16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on).

Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.

Selinexor 100 mg on days 1, 8, 15 and 22.

20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22

Autres noms:
  • Dextenza, Ozurdex, Neofordex, autres

Selinexor 100 mg PO on days 1, 8, 15 and 22

Autres noms:
  • KPT-330

16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on

Autres noms:
  • Darzalex

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Overall Response Rate (ORR) of patients receiving selinexor with carfilzomib and dexamethasone (Arm 1)
Délai: 30 Months

ORR will include patients who experience partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR), based on International Myeloma Working Group (IMWG) response criteria (Kumar 2016)

30 Months
Overall Response Rate (ORR) of patients receiving selinexor with pomalidomide and dexamethasone (Arm 2)
Délai: 30 Months

ORR will include patients who experience partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR), based on International Myeloma Working Group (IMWG) response criteria (Kumar 2016)

30 Months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Progression Free Survival (PFS)
Délai: 30 Months

Duration from start of study treatment to PD or death [regardless of cause], whichever comes first

30 Months
Overall Survival (OS)
Délai: 30 Months

Duration from start of study treatment to death

30 Months
MRD Negativity
Délai: 30 Months

Rate of achievement of minimal residual disease (MRD) by multiparametric flow cytometry

30 Months
Incidence of Adverse Events [Safety and Tolerability] using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v 4.03.
Délai: 30 Months

Incidence of Adverse Events [Safety and Tolerability] using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v 4.03.

30 Months
Time To Next Treatment (TTNT)
Délai: 30 Months

Duration from start of study treatment to next treament

30 Months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Overall Response Rate (ORR) of patients receiving selinexor with daratumumab and dexamethasone
Délai: 30 Months

ORR will include patients who experience partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR), based on International Myeloma Working Group (IMWG) response criteria (Kumar 2016)

30 Months
Gut Microbiome analysis
Délai: 30 Months

To identify intestinal microbiota associated biomarkers that predict response and risk for development of treatment-related toxicities at baseline, on-treatment, post-treatment and relapse.

30 Months
Immune cell subset analyses
Délai: 30 Months

Changes from baseline in immune cell subsets in peripheral blood mononuclear and bone marrow mononuclear cells will be monitored.

30 Months
Analyses of cytokine markers
Délai: 30 Months

Cytokines will be quantified in plasma samples by multiplex ELISA and other readout assays.

30 Months
Analyses of chemokine markers
Délai: 30 Months

Chemokines will be quantified in plasma samples by multiplex ELISA and other readout assays.

30 Months
Analyses of inflammatory/anti-inflammatory markers
Délai: 30 Months

Inflammation/anti-inflammation markers will be quantified in plasma samples by multiplex ELISA and other readout assays.

30 Months
Analyses of bacterial translocation markers
Délai: 30 Months

Bacterial translocation markers will be quantified in plasma samples by multiplex ELISA and other readout assays.

30 Months
Basic peripheral blood laboratory variables: Lymphocytes
Délai: 30 Months

Basic peripheral blood laboratory value of absolute and relative lymphocytes obtained in routine clinical care will be evaluated prior to treatment, on-treatment, post-treatment, relapse and at development of severe AE (>3 score).

30 Months
Basic peripheral blood laboratory variables: Eosinophils
Délai: 30 Months

Basic peripheral blood laboratory value of absolute and relative eosinophils obtained in routine clinical care will be evaluated prior to treatment, on-treatment, post-treatment, relapse and at development of severe AE (>3 score).

30 Months
Basic peripheral blood laboratory variables: Monocytes
Délai: 30 Months

Basic peripheral blood laboratory value of absolute and relative monocytes obtained in routine clinical care will be evaluated prior to treatment, on-treatment, post-treatment, relapse and at development of severe AE (>3 score).

30 Months
Basic peripheral blood laboratory variables: Neutrophils
Délai: 30 Months

Basic peripheral blood laboratory value of absolute and relative neutrophils obtained in routine clinical care will be evaluated prior to treatment, on-treatment, post-treatment, relapse and at development of severe AE (>3 score).

30 Months
Basic peripheral blood laboratory variables: Basophils
Délai: 30 Months

Basic peripheral blood laboratory value of absolute and relative basophils obtained in routine clinical care will be evaluated prior to treatment, on-treatment, post-treatment, relapse and at development of severe AE (>3 score).

30 Months
Basic peripheral blood laboratory variables: LDH
Délai: 30 Months

Basic peripheral blood laboratory value of LDH obtained in routine clinical care will be evaluated prior to treatment, on-treatment, post-treatment, relapse and at development of severe AE (>3 score).

30 Months
Basic peripheral blood laboratory variables: Neutrophil-to-lymphocyte ratio (NLR)
Délai: 30 Months

Basic peripheral blood laboratory value of absolute neutrophil-to-lymphocyte ratio (NLR) obtained in routine clinical care will be evaluated prior to treatment, on-treatment, post-treatment, relapse and at development of severe AE (>3 score).

30 Months
Analyses of genetic profiles
Délai: 30 Months

Exploratory analysis to identify molecular genomic determinants of response or resistance to selinexor in the treatment combinations to define biomarkers

30 Months
Analyses of markers of de novo or acquired resistance to treatment
Délai: 30 Months

Exploratory analysis to identify mechanisms of de novo or acquired resistance to selinexor in combination with carfilzomib, pomalidomide or daratumumab.

30 Months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Noa Biran, MD, Hackensack Meridian Health

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 mars 2021

Achèvement primaire (Estimé)

1 février 2028

Achèvement de l'étude (Estimé)

1 février 2028

Dates d'inscription aux études

Première soumission

3 décembre 2020

Première soumission répondant aux critères de contrôle qualité

3 décembre 2020

Première publication (Réel)

10 décembre 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner